Lecture Recitals

Recital presented in partial fulfillment of the Doctor of Musical Arts (DMA) degree

Nickel Allergy Is a Risk Factor for Endometriosis: An 11-Year Population-Based Nested Case-Control Study.

A cross-sectional study has reported that nickel allergy is associated with endometriosis. However, causal studies of this association are limited.The objective of this study was to compare the prevalence of nickel allergy in women with and without endometriosis.We used a National Health Insurance Service (NHIS) sample cohort dataset that included approximately 1 million individuals from South Korea; the data were obtained between January 01, 2002, and December 31, 2013. We selected the endometriosis group according to diagnosis code (N80.X), surgery codes, and drug codes during the years 2009~2013. The controls were randomly matched to the endometriosis patients at a ratio of 4:1 by age and socioeconomic status. Patients with nickel allergy were defined in the cohort dataset as those with a simultaneous diagnosis code (L23.0) and patch test code during 2002~2008.In total, 4,985 women were selected from the NHIS cohort database and divided into an endometriosis group (997 women) and a control group (3,988 women). The number of patients with nickel allergy in the endometriosis group was eight (0.8%), and that in the control group was thirteen (0.3%). After adjustment for age and socioeconomic status, the rate of nickel allergy in was higher in the endometriosis group than in the control group [odds ratio: 2.474; 95% confidence interval: 1.023~5.988; p = 0.044].We found that nickel allergy is a risk factor for endometriosis

Multivariate logistic regression analysis of endometriosis and nickel allergy.

<p>^a Covariates: Age group per 5 years, socioeconomic status group (decile), nickel allergy.</p><p>CI, Confidence interval; OR, Odds ratio</p><p>Multivariate logistic regression analysis of endometriosis and nickel allergy.</p

Characteristics of patients in the endometriosis group and the control group, 2002–2013.

<p>^a First diagnosis of EMS was made in the year noted.</p><p>^b Mean age groups per 5 years in 2013. 1; 0–4 years, 2; 5–9 years,……., 17; 80–84 years, 18; 85 years+.</p><p>^c The mean age was calculated from the mean age groups per 5 years.</p><p>^d Mean socioeconomic status groups in 2013. 1; upper 0–9%, 2; upper 10–14%,……., 9; upper 90–94%, 10; upper 95%+.</p><p>^e Fisher’s exact test</p><p>Data are presented as numbers or means ± standard deviations</p><p>Characteristics of patients in the endometriosis group and the control group, 2002–2013.</p

Flow chart representing the selection procedure based on the NHIS cohort data set from 2002–2013.

<p>^a Surgery codes: R4122, R4160, R4165, R4166, R4170, R4181, R4182, R4183, R4331, R4332, R4341, R4342, R4345, R4421, R4430, and R4435. ^b Gonadotropin-releasing hormone agonist codes and danazol codes: 182602BIJ, 182604BIJ, 244902BIJ, 167202BIJ, 167201BIJ, 198501CSI, 140301ACH, and 140302ACH. Abbreviations: EMS, Endometriosis; NHIS, National Health Insurance Service; GnRH, Gonadotropin-releasing hormone.</p

Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities

The heterogeneity of IDH1/2 wild-type glioblastoma limits its prognosis and therapy. Here, the authors show a binary stratification, based on quantitative proteomic analysis of samples from patients with glioblastoma, with different prognosis and therapeutic vulnerabilities